All Insights White Paper Do Pharma Companies Need To Rethink Their Sales Operations Design?

    Do Pharma Companies Need To Rethink Their Sales Operations Design?

    Sales Operations

    Do Pharma Companies Need To Rethink Their Sales Operations Design?

    Do Pharma Companies Need To Rethink Their Sales Operations Design?

    The COVID-19 pandemic has brought about many long-term changes to the pharma industry. One area that has seen effects directly caused by COVID-19 has been in sales operations design, management, and engagement with customers due to increased access restrictions of sales reps to physicians. COVID-19 has also accelerated institutional rethinking of the level and role of direct sales forces in the pharma industry. This white paper explores why pharma companies need to explore these changes. Companies need to prepare for changing the size and objective of direct sales forces given the effects of COVID-19 and the impact of existing environmental trends highlighted by the pandemic.

    Contact us at insights@axtria.com with any questions.

    Complete the brief form to download the white paper

    Recommended insights

    Pharma Sales Operations Design White Paper

    White Paper

    Do Pharma Companies Need To Rethink Their Sales Operations Design?

    Pharma Sales Operations Design White Paper

    Blog

    Continued Need for Pharmaceutical Economic Analysis of COVID-19 Induced Effects on Drug Demand

    Pharma Sales Operations Design White Paper

    White Paper

    Why The COVID-19 Recession Is Different And More Dangerous Than The Great Recession